Tetracycline and viruses: a possible treatment for COVID-19?

Arch Virol. 2021 Jan;166(1):1-7. doi: 10.1007/s00705-020-04860-8. Epub 2020 Nov 2.

Abstract

Tetracyclines have been used to treat many bacterial infections. The use of these antibiotics for the treatment of viral diseases dates to the 1960s to 1970s. Over the decades, the effect of tetracyclines on the pathogenesis of viral infections has been demonstrated both clinically and experimentally. Tetracyclines can act on viral infections either through their antibacterial properties or through direct antiviral action. This review focuses on clinical and experimental data that support the use of tetracycline in treating viral infections and highlights an important approach to slowing disease progression during viral infections. Tetracycline treatment might represent a strategy for eliminating the infection or inhibiting the progression of COVID-19.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Apoptosis / drug effects
  • COVID-19 Drug Treatment*
  • Disease Progression
  • Humans
  • SARS-CoV-2 / drug effects*
  • Tetracyclines / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Antiviral Agents
  • Tetracyclines